Institution
Peking Union Medical College Hospital
Healthcare•Beijing, China•
About: Peking Union Medical College Hospital is a healthcare organization based out in Beijing, China. It is known for research contribution in the topics: Medicine & Population. The organization has 15996 authors who have published 16018 publications receiving 226505 citations.
Topics: Medicine, Population, Cancer, Lung cancer, Internal medicine
Papers published on a yearly basis
Papers
More filters
••
Uppsala University1, Karolinska University Hospital2, University of Vermont3, Universidade Federal de Minas Gerais4, Universidade Católica de Pelotas5, University of Tokyo6, Fujita Health University7, Central University of Venezuela8, University of Trieste9, University of Cape Town10, Monash University11, University of Warwick12, Ohio State University13, University of Alberta14, Hospital General de México15, University of Waterloo16, American Society for Parenteral and Enteral Nutrition17, Brigham and Women's Hospital18, Saint Louis University Hospital19, Sapienza University of Rome20, Khon Kaen University21, HAN University of Applied Sciences22, VU University Amsterdam23, Tel Aviv University24, Rabin Medical Center25, University of Illinois at Chicago26, Pontifical Catholic University of Chile27, University of São Paulo28, Peking Union Medical College Hospital29, Free University of Brussels30, University of Pennsylvania31
TL;DR: This initiative is focused on building a global consensus around core diagnostic criteria for malnutrition in adults in clinical settings.
Abstract: Rationale
This initiative is focused on building a global consensus around core diagnostic criteria for malnutrition in adults in clinical settings.
827 citations
••
TL;DR: It is clear that finding an effective antiviral and developing a vaccine are still significant challenges, as the SARS-CoV-2 virus has led to significant sociological, psychological and economic effects globally.
769 citations
••
Shanghai University1, Peking Union Medical College2, Capital Medical University3, Peking Union Medical College Hospital4, Zhengzhou University5, Qingdao University6, Xi'an Jiaotong University7, Li Ka Shing Faculty of Medicine, University of Hong Kong8, University of Macau9, Russian Academy of Sciences10, University of Valencia11, Maharishi Markandeshwar University, Mullana12, Inha University13, King's College London14, University of Palermo15, University of North Texas Health Science Center16
TL;DR: The intravenous transplantation of MSCs was safe and effective for treatment in patients with COVID-19 pneumonia, especially for the patients in critically severe condition.
Abstract: A coronavirus (HCoV-19) has caused the novel coronavirus disease (COVID-19) outbreak in Wuhan, China. Preventing and reversing the cytokine storm may be the key to save the patients with severe COVID-19 pneumonia. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. This study aims to investigate whether MSC transplantation improves the outcome of 7 enrolled patients with COVID-19 pneumonia in Beijing YouAn Hospital, China, from Jan 23, 2020 to Feb 16, 2020. The clinical outcomes, as well as changes of inflammatory and immune function levels and adverse effects of 7 enrolled patients were assessed for 14 days after MSC injection. MSCs could cure or significantly improve the functional outcomes of seven patients without observed adverse effects. The pulmonary function and symptoms of these seven patients were significantly improved in 2 days after MSC transplantation. Among them, two common and one severe patient were recovered and discharged in 10 days after treatment. After treatment, the peripheral lymphocytes were increased, the C-reactive protein decreased, and the overactivated cytokine-secreting immune cells CXCR3+CD4+ T cells, CXCR3+CD8+ T cells, and CXCR3+ NK cells disappeared in 3-6 days. In addition, a group of CD14+CD11c+CD11bmid regulatory DC cell population dramatically increased. Meanwhile, the level of TNF-α was significantly decreased, while IL-10 increased in MSC treatment group compared to the placebo control group. Furthermore, the gene expression profile showed MSCs were ACE2- and TMPRSS2- which indicated MSCs are free from COVID-19 infection. Thus, the intravenous transplantation of MSCs was safe and effective for treatment in patients with COVID-19 pneumonia, especially for the patients in critically severe condition.
765 citations
••
Ben-Gurion University of the Negev1, McMaster University2, Population Health Research Institute3, University of North Carolina at Chapel Hill4, Sanjay Gandhi Post Graduate Institute of Medical Sciences5, University of Gothenburg6, Katholieke Universiteit Leuven7, Iuliu Hațieganu University of Medicine and Pharmacy8, Peking Union Medical College Hospital9, Tohoku University10, University of Sydney11, University of Jos12, Cornell University13, National Autonomous University of Mexico14, University of Manchester15, University of Ghana16, Isfahan University of Medical Sciences17, University of Amsterdam18, Ege University19, Wonkwang University20, Universidade Federal do Rio Grande do Sul21, Pontifical Xavierian University22, Moscow State University of Medicine and Dentistry23, Universiti Sains Malaysia24, Wrocław Medical University25, Dhaka Medical College and Hospital26, Autonomous University of Barcelona27, University of Cape Town28, University of Indonesia29, Queen's University30, National University of Singapore31, Rabin Medical Center32, University of Alberta33, Mazandaran University of Medical Sciences34, Université de Montréal35
TL;DR: It is found that more than 40% of persons worldwide have FGIDs, which affect quality of life and healthcare use, and similar trends and relative distributions were found in people who completed internet vs personal interviews.
763 citations
••
Sichuan University1, Clinical Trial Service Unit2, Capital Medical University3, The George Institute for Global Health4, University of Edinburgh5, Peking University6, Peking Union Medical College Hospital7, Chinese PLA General Hospital8, China Rehabilitation Research Center9, Nanjing University10, Huazhong University of Science and Technology11, Chongqing Medical University12, The Chinese University of Hong Kong13
TL;DR: Future efforts should focus on providing more balanced availability of specialised stroke services across the country, enhancing evidence-based practice, and encouraging greater translational research to improve outcome of patients with stroke.
Abstract: With over 2 million new cases annually, stroke is associated with the highest disability-adjusted life-years lost of any disease in China. The burden is expected to increase further as a result of population ageing, an ongoing high prevalence of risk factors (eg, hypertension), and inadequate management. Despite improved access to overall health services, the availability of specialist stroke care is variable across the country, and especially uneven in rural areas. In-hospital outcomes have improved because of a greater availability of reperfusion therapies and supportive care, but adherence to secondary prevention strategies and long-term care are inadequate. Thrombolysis and stroke units are accepted as standards of care across the world, including in China, but bleeding-risk concerns and organisational challenges hamper widespread adoption of this care in China. Despite little supporting evidence, Chinese herbal products and neuroprotective drugs are widely used, and the increased availability of neuroimaging techniques also results in overdiagnosis and overtreatment of so-called silent stroke. Future efforts should focus on providing more balanced availability of specialised stroke services across the country, enhancing evidence-based practice, and encouraging greater translational research to improve outcome of patients with stroke.
740 citations
Authors
Showing all 16286 results
Name | H-index | Papers | Citations |
---|---|---|---|
Feng Zhang | 172 | 1278 | 181865 |
Jian Li | 133 | 2863 | 87131 |
Shuai Liu | 129 | 1095 | 80823 |
Jun Yu | 121 | 1174 | 81186 |
Edward M. Brown | 111 | 489 | 44630 |
Qian Wang | 108 | 2148 | 65557 |
Ming Li | 103 | 1669 | 62672 |
Tao Li | 102 | 2483 | 60947 |
Masatoshi Kudo | 100 | 1324 | 53482 |
Christophe Tzourio | 98 | 475 | 53680 |
Yang Xin Fu | 97 | 390 | 33526 |
Michael Q. Zhang | 93 | 378 | 42008 |
Xiang Gao | 92 | 1359 | 42047 |
Jun Li | 90 | 339 | 61485 |
Honglei Chen | 80 | 207 | 83906 |